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In Brief
It has been difficult to selectively disrupt
mitochondrial redox state, independently
of that in the rest of the cell. Here, Booty
et al. introduce MitoCDNB to deplete
mitochondrial glutathione and selectively
inhibit key enzymatic components of
mitochondrial thiol redox status in cells
and in vivo..
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Mitochondrial glutathione (GSH) and thioredoxin (Trx)
systems function independently of the rest of the cell.
While maintenance of mitochondrial thiol redox state
is thought vital for cell survival, this was not testable
due to the difficulty of manipulating the organelle’s
thiol systems independently of those in other cell
compartments. To overcome this constraint we
modified the glutathione S-transferase substrate
and Trx reductase (TrxR) inhibitor, 1-chloro-2,4-dini-
trobenzene (CDNB) by conjugation to the mitochon-
dria-targeting triphenylphosphonium cation. The
result, MitoCDNB, is taken up bymitochondria where
it selectively depletes the mitochondrial GSH pool,
catalyzed by glutathione S-transferases, and directly
inhibits mitochondrial TrxR2 and peroxiredoxin 3, a
peroxidase. Importantly, MitoCDNB inactivatesmito-
chondrial thiol redox homeostasis in isolated cells
and in vivo, without affecting that of the cytosol.
Consequently, MitoCDNB enables assessment of
the biomedical importance of mitochondrial thiol ho-
meostasis in reactive oxygen species production,
organelle dynamics, redox signaling, and cell death
in cells and in vivo.
INTRODUCTION
Thiol redox status within mitochondria is determined by the
organelle’s glutathione (GSH) and thioredoxin (Trx) systems,
which are critical for cell viability and function (Fernandez-Checa
et al., 1998; Go and Jones, 2013; Murphy, 2012) (Figure S1A).
Mitochondrial GSH protects against reactive oxygen species
(ROS), electrophiles, xenobiotics, and protein thiol oxidation
(Murphy, 2012) (Figure S1A). GSH is made in the cytosol and
then transported into mitochondria (Booty et al., 2015; Griffith
andMeister, 1985; Lu, 2013; Romero andSies, 1984;Wahll€ander
et al., 1979). The mitochondrial GSH pool is maintained
reduced by glutathione reductase, which couples glutathioneCell Chemical Biology 26, 449–461, Ma
This is an open access article under the CC BY-Ndisulfide (GSSG) reduction to the matrix NADP+/NADPH pool
(Eh415mV) (Murphy, 2012). GSH is then used by glutathione
peroxidases (GPXs) 1 and 4, glutathione S-transferases (GSTs),
glutaredoxin-2, and ATP binding cassette transporters to main-
tain mitochondrial function (Hayes et al., 2005; Lillig et al.,
2008; Murphy, 2012; Ribas et al., 2014). Importantly, the mito-
chondrial GSH pool composition and activity are independent
of the cytosol (Figure S1A) (Booty et al., 2015; Griffith and Meis-
ter, 1985;Martensson et al., 1990). Themitochondrial Trx system
comprises Trx2, which is maintained reduced by coupling to
NADP+/NADPH through the reductase TrxR2 (Arner and Holmg-
ren, 2000; Lillig and Holmgren, 2007) (Figure S1A). Trx2 reduces
protein disulfides and maintains activity of the peroxidase, per-
oxiredoxin 3 (Prx3) (Cox et al., 2010), and of the mitochondrial
methionine sulfoxide reductases A and B2 (Kim and Gladyshev,
2007). Together, mitochondrial GSH and Trx systems maintain
mitochondrial thiol homoeostasis and their disruption contrib-
utes to a range of pathologies (Go and Jones, 2013; Murphy,
2012) (Figure S1A).
To explore how mitochondrial thiol redox homeostasis affects
health and disease, it is important to manipulate it acutely inde-
pendently of thiol redox state elsewhere in the cell. Ablation of
the genes underlying mitochondrial thiol status is challenging
because: GSH is imported into mitochondria after synthesis in
the cytosol and the transporter is not known (Booty et al.,
2015); GPXs are found in multiple locations in the cell (Kelner
and Montoya, 2000); and knock out of GPx4 or Trx reductase
2 (TrxR2) is embryonic lethal (Conrad, 2009). Consequently, we
sought chemical biology approaches to simultaneously and
selectively disrupt mitochondrial GSH and Trx systems indepen-
dently of the rest of the cell.
1-Chloro-2,4-dinitrobenzene (CDNB) is a GST substrate that
depletes GSH by forming 1-S-glutathionyl-2,4-dinitrobenzene
(GSDNB) (Habig et al., 1974a; Han et al., 2003; Hayes et al.,
2005) (Figure S1B). CDNB also inhibits mammalian TrxRs by al-
kylating the active site selenol (Arne´r et al., 1995; Nordberg et al.,
1998; Urig and Becker, 2006) (Figure S1B), thereby converting
TrxRs to a peroxide-generating NADPH oxidase (Zhong et al.,
1998). However, CDNB acts indiscriminately throughout the
cell; therefore, we modified CDNB to target it selectively to mito-
chondria so that it would only affect the organelle. To do this, we
conjugated CDNB to the triphenylphosphonium (TPP) cation torch 21, 2019 ª 2018 The Author(s). Published by Elsevier Ltd. 449
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Mode of Action of MitoCDNB
(A) MitoCDNB reaction with GSH catalyzed by GST
to form MitoGSDNB and deplete GSH. Inhibition of
TrxR2 by MitoCDNB by alkylation of its active site
selenol.
(B) The mitochondria-targeting TPP of MitoCDNB
leads to its selective accumulation within the mito-
chondrial matrix in vivo, driven by the plasma (Dcp)
and mitochondrial (Dcm) membrane potentials.
Within mitochondria the CDNB moiety is as a GST
substrate to deplete GSH, and also a TrxR2 inhibi-
tor. Thus MitoCDNB selectively disrupts mitochon-
drial thiol homeostasis through its effects on the
GSH and Trx systems.
See also Figure S1.make mitochondria-targeting CDNB (MitoCDNB) (Figure 1A).
The TPP cation rapidly targets molecules tomitochondria in cells
and in vivo, leading to the several-hundred-fold accumulation of
the compound within the mitochondrial matrix in response to the
mitochondrial and plasma membrane potentials (Ross et al.,
2005; Smith et al., 2011, 2012). The selective localization of
TPP within mitochondria means that these compounds only
act within the organelle, leaving the rest of the cell unaffected.
Hence, MitoCDNB should only disrupt mitochondrial thiol ho-
meostasis by depleting GSH and inhibiting TrxR2, without
affecting thiols elsewhere in the cell (Figure 1B). Here we show
that MitoCDNB selectively disrupts mitochondrial GSH and Trx
systems in isolated cells and in vivo, enabling the many roles
of the mitochondrial thiol homeostasis in health and disease to
be explored.
RESULTS
Synthesis and Reactivity of MitoCDNB
MitoCDNB (Figures 1A and 1B) is based on GST-activated pro-
drugs (Findlay et al., 2004; Morales and Laborde, 2007) and is a
derivative of 2,4-dinitrobenzene with a chlorine atom at C-1,450 Cell Chemical Biology 26, 449–461, March 21, 2019which is displaced by GSH, as well as an
alkylamino group at C-3, which does not
disrupt GST activity and is retained after
the conjugation reaction (Findlay et al.,
2004). MitoCDNB was synthesized by the
reaction of 1,5-dichloro-2,4-dinitrobenzene
with (4-aminobutyl)triphenylphosphonium
bromide, followed by ion exchange to
generate themesylate salt (STARMethods).
MitoGSDNB was synthesized by incuba-
tion of MitoCDNB with GSH (STAR
Methods). UV-vis spectra showed that
conjugation of GSH with MitoCDNB to
form MitoGSDNB dramatically increased
absorbance at 328 nm (Figure S2A), similar
to when GSH reacts with CDNB (Fig-
ure S2B) (Habig et al., 1974b). Addition of
GST-k, the predominant GST isoform
within mammalian mitochondria (Goto
et al., 2009; Hayes et al., 2005; Jowsey
et al., 2003; Murphy, 2012; Raza, 2011),or an isolatedmitochondrial matrix extract, initiated a rapid reac-
tion between GSH and MitoCDNB (Figures 2A and S2C).
Reverse-phase high-performance liquid chromatography
(RP-HPLC) (Figures 2B and S2D) and mass spectrometry (MS)
(Figure 2C) confirmed that GST-k catalyzed the reaction of Mi-
toCDNB (m/z = 534) with GSH to form MitoGSDNB (m/z =
805). Matrix fractions from heart, liver, and kidney mitochondria
all contained GST activity that catalyzed the formation of
MitoGSDNB from MitoCDNB, with by far the highest activity in
the liver, 10-fold higher than in the kidney (Baars et al., 1981)
(Figure S2E). Furthermore, the product of this reaction,
MitoGSDNB, only affected GST activity at concentrations of
around 100 mM (Figure S2F).
MitoCDNB inhibited recombinant mammalian cytosolic
TrxR1 (Figure 2D) and mitochondrial TrxR2 (Figure 2D, inset).
Western blotting for the TPP moiety showed that MitoCDNB
alkylated TrxR1 (Figure 2E), consistent with MitoCDNB
alkylating the active site selenol (Figure 1A). MitoCDNB also
alkylated Trx1 (Figure S2G) and Prx1 (Figure S2H), consistent
with inhibition of these proteins by alkylation of their reac-
tive thiols. Thus MitoCDNB can both deplete GSH and inhibit
TrxR2.
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Figure 2. Reactivity of MitoCDNB In Vitro
(A and B) GST-catalyzed reaction of MitoCDNBwith GSH. (A) MitoCDNB (10 mM) was incubated ± GSH (1mM) with GST-k (10 mg) or mitochondrial matrix extract
(100 mg protein), and absorbance at 328 nm measured. (B) MitoCDNB (10 mM) was incubated with GSH (1 mM) for 10 min alone (top), or with GST-k (100 mg,
(legend continued on next page)
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Mitochondria Accumulate MitoCDNB and Convert It to
MitoGSDNB
MitoCDNB is designed to accumulate within energized mito-
chondria (Figure 1B). To assess this, we used a TPP-selective
electrode to measure the MitoCDNB uptake (Figure 2F). Addi-
tion of de-energized mitochondria led to adsorption of
the compound to membranes, while subsequent generation
of a membrane potential by addition of succinate caused
MitoCDNB uptake that was partially reversed by dissipation
of the membrane potential with the uncoupler carbonyl cyanide
4-(trifluoromethoxy)phenylhydrazone (FCCP) (Figure 2F). How-
ever, only some of the accumulated MitoCDNB was released
upon uncoupling (Figure 2F), and lengthening the incubation
time between succinate and FCCP additions decreased
MitoCDNB release (Figure 2G). This is consistent with the
membrane-potential-dependent accumulation of MitoCDNB
followed by its reaction with GSH to form themembrane-imper-
meant MitoGSDNB. Supporting this, addition of alamethicin to
form pores in the mitochondrial inner membrane, led to com-
plete release of both MitoCDNB and MitoGSDNB (Figure 2G).
To confirm that MitoCDNB was converted to MitoGSDNB
within mitochondria we pelleted and extracted the mitochon-
dria followed by RP-HPLC (Figures 2H and S3A). This showed:
mitochondria incubated with MitoCDNB contain MitoCDNB
and MitoGSDNB (i); prior addition of FCCP decreased both
the uptake of MitoCDNB and its transformation to MitoGSDNB
(ii); addition of FCCP after incubation with MitoCDNB
decreased levels of MitoCDNB, but not of MitoGSDNB (iii);
finally, alamethicin released both MitoCDNB and MitoGSDNB
from mitochondria (iv). Analysis by MS of mitochondrial pellets
found MitoCDNB (m/z = 534) and MitoGSDNB (m/z = 805) (Fig-
ure S3B, upper trace), and only those two m/z values were
detected in a precursor ion scan using a product m/z of
183, diagnostic of TPP fragmentation (Figure S3B, lower
trace). Finally, quantification of MitoCDNB and MitoGSDNB
in the mitochondrial pellet and supernatant over time by RP-
HPLC confirmed that MitoCDNB was taken up rapidly by mito-
chondria and there converted to MitoGSDNB (Figures 2I
and S3C).bottom) and then analyzed by RP-HPLC at 220 nm (TPP, blue) and 328 nm (
compounds (Figure S2D).
(C) Mass spectrometric analysis of MitoCDNB reaction with GSH. MitoCDNB wa
analyzed by mass spectrometry.
(D) Mammalian TrxR1 and TrxR2 inhibition by MitoCDNB. TrxR1 (25 mg) was incu
MitoCDNB inhibition of TrxR2 in matrix extracts (25 mg protein) from rat liver (L),
vehicle (gray) for 5 min and then assessed for TxR2 activity (units = nmol NADPH
(E) Alkylation of TrxR1 by MitoCDNB. TrxR1 (20 mg) was incubated for 10 min w
MitoCDNB for 10 min (CDNB + MitoCDNB) or EtOH control (0.1%). Protein was
antiserum (bottom).
(F) MitoCDNB uptake by mitochondria. An electrode sensitive to the TPP moiety
chondria (2 mg protein/mL) were then added, followed by succinate (10 mM) and
(G) Time dependence ofMitoCDNB release frommitochondria upon uncoupling. M
times 1 mM FCCP or 5 mg/mL alamethicin was added.
(H) RP-HPLC ofmitochondrial MitoCDNB uptake. Livermitochondria were incubat
4 min followed by MitoCDNB for 5 min; (iii) with MitoCDNB and succinate for 5
followed by alamethicin for 4 min. Mitochondria and supernatants (Figure S3C) w
(I) Time dependence of uptake and transformation of MitoCDNB. Mitochondria
supernatant (bottom) fractions analyzed by RP-HPLC for MitoCDNB (red) orMitoG
in black.
Data are means ± SEM, N = 3. Traces are representative of >3 independent exp
452 Cell Chemical Biology 26, 449–461, March 21, 2019MitoCDNB Depletes Mitochondrial GSH and
Inhibits TrxR2
MitoCDNB depleted mitochondrial GSH in a dose-dependent
manner, with more than 90% depleted by 10 mM MitoCDNB,
while neither TPP molecule methyltriphenylphosphonium
(TPMP) nor MitoGSDNB affected GSH (Figure 3A). The rate of
mitochondrial GSH depletion by MitoCDNB was rapid and
attenuated by slowing its uptake by uncoupling with FCCP (Fig-
ure 3B), while mitochondrial GSH depletion by CDNBwas slower
and unaffected by FCCP (Figure 3B). MitoCDNB inhibited
mitochondrial TrxR2 activity and preventing MitoCDNB uptake
with FCCP diminished this inhibition (Figure 3C). CDNB also
affected TrxR2 activity, but again this inhibition was unchanged
by FCCP (Figure 3C). Western blotting of mitochondria after in-
cubation with MitoCDNB showed that it bound to mitochondrial
thiol proteins and that this was prevented by the thiol reagent
N-ethyl maleimide, or with FCCP (Figure S3D). This thiol pro-
tein-binding was similar to that of another TPP compound conju-
gated to a thiol-reactive group that does not deplete protein
thiols nor disrupt mitochondrial function, iodobutyltriphenyl-
phosphonium (Lin et al., 2002; Ross et al., 2008) (Figure S3E).
MitoCDNB also has little impact on mitochondrial respiration or
membrane potential (Figures S3F and S3G), hence its effects
on mitochondrial function will be secondary to disrupting the
GSH and Trx systems. We conclude that MitoCDNB is taken
up by energized mitochondria and there both inhibits TrxR2
and is also converted to MitoGSDNB by matrix GSTs.
Uptake and Transformation of MitoCDNB by Cells in
Culture
To facilitate assessment of MitoCDNB distribution and meta-
bolism to MitoGSDNB we set up a liquid chromatography-
tandem MS (LC-MS/MS) assay (STAR Methods). MitoCDNB
and MitoGSDNB both fragmented to a product ion of m/z of
183, diagnostic of TPP cations (Cocheme et al., 2011; Logan
et al., 2014), enabling selective and sensitive quantification of
MitoCDNB and MitoGSDNB in cells and in vivo. MitoCDNB
hadminimal effects on cell growth and survival at concentrations
below about 30 mM (Figures S4A and S4B) and both MitoCDNBMitoGSDNB, red). Peak identities were confirmed by spiking with authentic
s incubated with GSH (top) or with GSH + GST-k (bottom) as in (B) above then
bated with MitoCDNB for 10 min and then assessed for TrxR1 activity. Inset:
heart (H), or kidney (K) mitochondria, incubated with 5 mM MitoCDNB (red) or
min1 mg protein1).
ith 20 mM MitoCDNB (MitoCDNB), 20 mM CDNB for 5 min followed by 20 mM
then assessed by western blotting for TrxR1 (top) and reprobed with anti-TPP
of MitoCDNB was calibrated (5 3 1 mM MitoCDNB, red arrows). Liver mito-
1 mM FCCP. A representative trace is shown of three replicates.
itochondria were incubatedwith 10 mMMitoCDNB as in (F) and at the indicated
ed with 10 mMMitoCDNB as in (F): (i) withMitoCDNB for 9min; (ii) with FCCP for
min followed by FCCP for 4 min; (iv) with MitoCDNB and succinate for 5 min
ere then analyzed by RP-HPLC.
were incubated with MitoCDNB as in (H) and then mitochondrial (top) and
SDNB (blue). Peak areas are in a.u and the normalized sum of the peak areas is
eriments. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figures S2 and S3.
AC
B
D E
F G
Figure 3. Impact of MitoCDNB on Mitochondrial GSH and TrxR
(A) MitoCDNB depletes mitochondrial GSH. Liver mitochondria (2 mg protein/mL) were incubated with vehicle, MitoCDNB, CDNB, TPMP, or MitoGSDNB for
5 min, then matrix glutathione levels were determined.
(B) Time course of GSH depletion. MitoCDNB (10 mM) or CDNB (10 mM) were incubated with mitochondria, then matrix glutathione levels determined. For some
experiments FCCP (1 mM) was added prior to MitoCDNB or CDNB (dotted lines).
(legend continued on next page)
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and MitoGSDNB were stable in culture media (Figure S4C). We
then measured the uptake of MitoCDNB into HepG2 cells and
its conversion to MitoGSDNB over time (Figure 3D). Surprisingly,
only very small amounts of MitoCDNB, and noMitoGSDNB, was
found in HepG2 cells (Figure 3D). However, there was a substan-
tial decrease in MitoCDNB and an increase of MitoGSDNB in the
incubation medium (Figure 3E). A similar pattern was found in
C2C12 cells (Figures S4D and S4E). These data suggest that
MitoCDNB enters cells, is rapidly converted to MitoGSDNB
and is then exported to the culture medium.
Intriguingly, for HepG2, but not C2C12 cells (Figures S4D and
S4E), the amount of MitoCDNB and MitoGSDNB that accumu-
lated in the medium was 150 pmol/mL less than the amount
of MitoCDNB added (Figure 3E). To see if other MitoCDNB deriv-
atives were formed we carried out a product scan on HepG2 cell
culture medium to identify precursor ions that generated a prod-
uct ion ofm/z of 183, diagnostic of a TPP cation. In addition to the
expected precursor ions of MitoCDNB (m/z = 534) and Mi-
toGSDNB (m/z = 805), another precursor ion was observed
with m/z of 618. This pattern is consistent with initial breakdown
of MitoGSDNB by a g-glutamyl transpeptidase (GGT) to remove
the glutamyl unit giving MitoCysGlyDNB (m/z = 676), followed by
release of a glycine unit by a dipeptidase to yield S-MitoCysDNB
(m/z = 619). The free N terminus of the cysteine can then undergo
an S to N migration by a Smiles rearrangement (Kondo et al.,
1881), resulting in a free thiol product, N-MitoCysDNB of the
same m/z, auto-oxidation of which gives the corresponding di-
sulfide, N-MitoCysDNB disulfide (m/z = 618) (Figure 3F). Sup-
porting this, chemical synthesis of S-MitoCysDNB was followed
by a spontaneous Smiles rearrangement and auto-oxidation to
give an N-MitoCysDNB disulfide (STAR Methods). N/C-Mito-
CysDNB are unlikely to form from the direct reaction of cysteine
with MitoCDNB, as the uncatalyzed reaction of the cysteine thiol
of GSH with MitoCDNB is negligible, and cysteine is not a GST
substrate. As GGTs are highly expressed on the surface of liver
cells this may also explain why this transformation was seen in
the liver-derived HepG2 cells (Zhang et al., 2005), but not in
the muscle-derived C2C12 cells. To assess this further, we es-
tablished an LC-MS/MS assay for N-MitoCysDNB and used
this to assess the accumulation of MitoCysDNB during incuba-
tion of MitoCDNB with HepG2 cells (Figure 3G). The amount of
MitoCysDNB at the later stages of the time course was about
150 pmol/mL, accounting for the difference in recovery of the
starting material in HepG2 incubations (Figure 3E). In contrast,
very little MitoCysDNB accumulated upon incubatingMitoCDNB
with C2C12 cells (Figure S4F), presumably because the GGT
present on the extracellular face of HepG2 cells (Zhang et al.,
2005), is poorly expressed in C2C12 cells. This interpretation
was supported by incubating cell-impermeant MitoGSDNB(C) Inhibition of TrxR2 by MitoCDNB. Liver mitochondria (2 mg/mL) were incubate
blue). For some experiments FCCP (1 mM) was added before MitoCDNB (red, w
(D and E) Uptake and metabolism of MitoCDNB by cells. HepG2 cells were incub
cells (D) and medium (E) were quantified by LC-MS/MS. The sum of MitoCDNB
(F) Schematic of MitoCDNB metabolism. MitoCDNB reacts with GSH to form
extracellular g-glutamyl transpeptidase (GGT) to MitoCysGlyDNB, further conver
to N-MitoCysDNB, which autooxidizes to N-MitoCysDNB disulfide.
(G) Generation of MitoCysDNB in HepG2 cells. MitoCysDNB levels were quantifi
*p < 0.05, **p < 0.01, ***p < 0.001 relative to control; ##p < 0.01 relative to incuba
454 Cell Chemical Biology 26, 449–461, March 21, 2019with HepG2 cells with generic GGT inhibitor, acivicin, which
decreased breakdown of MitoGSDNB to MitoCysDNB (Fig-
ure S4G). In summary, MitoCDNB is taken up by cells and there
rapidly converted to MitoGSDNB before excretion, when it is
further converted into MitoCysDNB on the surface of liver cells.
MitoCDNB Depletes Mitochondrial GSH and Inhibits
TrxR2 in Cells
We next assessed the effects of MitoCDNB in HepG2 cells on
both total (Figure 4A) andmitochondrial GSH content (Figure 4B).
CDNB had a greater effect on the total cellular GSH levels than
MitoCDNB (Figure 4A). However, when we analyzed the effects
of MitoCDNB and CDNB on mitochondrial GSH we found that
MitoCDNBdepletedmore than 70%ofmitochondrial GSH, while
CDNB left the mitochondrial GSH unaffected (Figure 4B).
Analyzing the effects of MitoCDNB over time showed that
MitoCDNB rapidly depleted the mitochondrial GSH pool within
an hour, while the total cellular GSH remained unaffected (Fig-
ure 4C). Furthermore, preventing MitoCDNB uptake into
mitochondria with FCCP decreased the depletion of mitochon-
drial GSH (Figure 4D). Similar selective depletion of mitochon-
drial GSH by MitoCDNB was found in C2C12 cells (Figures
S4H–S4J).
Incubation of HepG2 cells with MitoCDNB decreased TrxR
activity by more than 60% in mitochondrial extracts, but had
less effect on the total cell TrxR activity (Figure 4E). To extend
this we compared the effect of MitoCDNB and CDNB on total
cell TrxR activity in C2C12 cells over time (Figure 4F). This
also showed that MitoCDNB had limited effect on whole-cell
TrxR activity compared with CDNB (Figure 4F). Thus, in cells
MitoCDNB selectively depletes the mitochondrial GSH pool
and TrxR2 activity while leaving the cytosolic GSH pool and
TrxR1 activity unaffected.
As MitoCDNB inhibits TrxR2 activity it would be expected to
slow the reduction of the disulfide dimer form of the mitochon-
drial peroxidase peroxiredoxin 3 (Prx3), which is formed as
part of its enzymatic cycle upon degrading hydrogen peroxide
(Cox et al., 2010). Surprisingly, there was no change in Prx3
dimerization in isolated mitochondria incubated with MitoCDNB.
One possibility was that MitoCDNB may alkylate the reactive
thiol of Prx3, as occurred for Prx1 (Figure S2G), thereby prevent-
ing Prx3 dimerization. To see if this was occurring, we incubated
cells with MitoCDNB and then assessed how this affected Prx3
dimerization in themitochondria and compared this to the dimer-
ization of Prx2 in the cytosol (Figures S5A and S5B). In the
absence of exogenous additions there were low and stable
levels of Prx dimerization in the mitochondrial matrix (Prx3) and
in the cytosol (Prx2); however, addition of the mitochondria-
targeted ROS generator MitoPQ, which only induces oxidatived for 5 min with either carrier (white), MitoCDNB (10 mM, red), or CDNB (10 mM,
hite) or CDNB (blue, white) for a further 5 min.
ated with MitoCDNB (10 mM) and then the MitoCDNB and MitoGSDNB in the
and MitoGSDNB is indicated.
MitoGSDNB in mitochondria. This is excreted and broken down by the
ted to S-MitoCysDNB, which undergoes a spontaneous Smiles rearrangement
ed in cells from (D) above and from media (E). Data are means ± SEM, N = 3.
tion without FCCP in (C) only. See also Figures S3 and S4.
A B C
D E
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Figure 4. SelectiveMitochondrial GSHDeple-
tion and TrxR2 Inactivation by MitoCDNB in
Cells
(A) Depletion of cell GSH. HepG2 cells were incu-
bated for 1 hr with MitoCDNB (10 mM), CDNB
(10 mM), or vehicle and cell GSH levels measured.
(B) Mitochondrial GSH depletion in cells. HepG2
cells were incubated as in (A), mitochondria were
then isolated and GSH measured.
(C) Time course of GSH depletion by MitoCDNB.
HepG2 cells were incubated as in (A) and total and
mitochondrial GSH measured.
(D) Effect of FCCP on mitochondrial GSH depletion.
HepG2 cells were incubated for 1 hr with MitoCDNB
(10 mM) alone, + FCCP (100 mM), or with vehicle, and
mitochondrial GSH assessed. **p < 0.01 relative to
control; ##p < 0.01 relative to FCCP.
(E) Inhibition of TrxR2 by MitoCDNB in cells. HepG2
cells were incubated with vehicle or MitoCDNB
(10 mM) for 4 hr. Total cell andmitochondrial extracts
were assessed for TrxR activity.
(F) Effect of MitoCDNB on cell TrxR activity.
Cells were incubated with 10 mM TPMP, CDNB,
MitoCDNB, or carrier, for 1, 4, or 24 hr and total
cell TrxR activity measured.
Data are means ± SEM, N = 4 (A–E) or 3 (F). *p <
0.5, **p < 0.01, ***p < 0.001 relative to control, or
time = 0 (C); #p < 0.05, ##p < 0.01 relative to CDNB
(B), FCCP (D) or cell + MitoCDNB (E). See also
Figures S4 and S5.stress in themitochondria (Robb et al., 2015), led to selective Prx
dimerization in the mitochondrial matrix (Figures S5A and S5B),
indicating that this approach could report on local changes in
oxidative stress within mitochondria. However, MitoCDNB did
not increase Prx3 dimerization alone nor did it enhance the
dimerization caused by MitoPQ (Figures S5A and S5B). To see
if this could be due to alkylation of reactive cysteines on Prx3
by MitoCDNB, we treated cells with the thiol oxidant diamide
to convert Prx3 to the dimeric form. Diamide enhanced dimeriza-
tion, but after treatment with MitoCDNB the ability of the Prx3
to dimerize upon addition of diamide was greatly diminished
(Figure S5C). Furthermore, western blotting of mitochondria
treated with MitoCDNB showed that Prx3 colocalized with
immunoreactivity against the TPP moiety of MitoCDNB (Fig-
ure S5D). Together these data indicate that MitoCDNB alkylates
and inactivates Prx3 by reacting with its active site cysteine
residue, thereby preventing it from degrading H2O2. Thus,
MitoCDNB selectively disrupts mitochondrial thiol redox meta-
bolism in cells while leaving that of the cytosol intact.
MitoCDNB Uptake, Metabolism, and Distribution In Vivo
As mitochondria-targeted compounds comprising a TPP cation
are readily taken up bymitochondria in vivo (Smith et al., 2003), it
should be possible to use MitoCDNB to selectively alter the thiol
redox state of mitochondria in experimental animals in vivo. To
assess this possibility we injected MitoCDNB (5 mg/kg) intoCell ChemicC57BL/6J mice as a bolus intravenous in-
jection and, after various times, the mice
were culled and the liver, heart, kidney,
and blood extracted and the amounts ofMitoCDNB, MitoGSDNB, and MitoCysDNB were quantified by
LC-MS/MS (Figures 5A, 5B, and S6A). This showed that after
5 min most of the MitoCDNB was cleared from the blood
and taken up by the tissues, and there rapidly converted to
MitoGSDNB with some detected in the blood. After 1 hr the
MitoGSDNB dominated in tissues and the amount of Mito-
CysDNB was negligible (Figures 5A, 5B, and S6A). Over the
next 3 hr MitoGSDNB was all gone, while MitoCDNB was about
60% depleted and was all gone after 24 hr, at which time there
was still extensive depletion of mitochondrial glutathione in
the liver and kidney (Figures 5A, 5B, S6A, and S6B). Analysis
of spot urines 24 hr after MitoCDNB injection showed accumula-
tion of both MitoCDNB andMitoCysDNB, but not of MitoGSDNB
(Figure 5C). Isolation of mitochondrial fractions from the liver
showed that the amount of MitoCDNB detected in themitochon-
drial fraction was negligible, while 120–200 pmol MitoGSDNB/
mg protein was detected up to 4 hr; however, it too was gone
after 24 hr (Figure 5D). Unlike MitoGSDNB, MitoCDNB is mem-
brane permeant and may be lost during mitochondrial isolation
as the organelles will no longer have a membrane potential.
Assessing the levels of these compounds in blood showed
that MitoCDNB in the blood was negligible, while 20 mM
MitoGSDNB accumulated over 4 hr, and the concentration of
MitoCysDNB rose to more than 75 mM in the same period
(Figure 5B). Thus, MitoCDNB is taken up by mitochondria and
there rapidly converted to MitoGSDNB, which is then excretedal Biology 26, 449–461, March 21, 2019 455
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Figure 5. Selective Depletion of Mitochondrial GSH and Inactivation of TrxR2 by MitoCDNB within Tissues In Vivo
Mice were injected with MitoCDNB (5 mg/kg) and tissues harvested for analysis of total and mitochondrial GSH content, and for TrxR activity.
(A) Liver levels of MitoCDNB and MitoGSDNB were quantified by LC-MS/MS.
(B) Blood samples were analyzed for MitoCDNB, MitoGSDNB, and MitoCysDNB by LC-MS/MS.
(C) Spot urines 24 hr after MitoCDNB injection were quantified for MitoCDNB, MitoGSDNB, and MitoCysDNB by LC-MS/MS.
(D) Liver mitochondrial levels of MitoCDNB and MitoGSDNB were quantified by LC-MS/MS.
(legend continued on next page)
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from the cell and then converted to MitoCysDNB for delivery to
the urine.
MitoCDNB Selectively Depletes Mitochondrial GSH and
Lowers TrxR Activity In Vivo
While MitoCDNB did enter mitochondria in vivo and formed
MitoGSDNB, it was then rapidly excreted from the cell and
body. Therefore it was unclear if the exposure to MitoCDNB
in vivo was sufficient to affect mitochondrial GSH and TrxR2 ac-
tivities. Thus we assessed how MitoCDNB injection affected
GSH levels, both in the whole tissue and also in mitochondrial
fractions from heart, kidney, and liver (Figure 5E). There was a
specific depletion of the mitochondrial GSH pool in both liver
and kidney, which started to return to control levels 7 days
post injection. Interestingly, the heart showed a slower depletion
of mitochondrial GSH, yet only recovered to 50% of control
levels after 7 days, suggesting tissue-specific differences in
repletion of the mitochondrial glutathione pool. This is consistent
with the slow recovery of the total heart GSH pool after GSH
depletion in mice (Lee et al., 1987; Gerard-Monnier et al.,
1992). In contrast to mitochondrial GSH the total GSH levels
in the tissues were not depleted, but actually increased by
20%–70% in all tissues 24 hr after MitoCDNB injection. In
response to MitoCDNB the expression of glutamate-cysteine
ligase (GCL), the rate-limiting enzyme for GSH synthesis,
increased by 6- to 7-fold. There was also a 50% increase in
glutathione synthetase expression (Figures 5F and 5G). This sug-
gests that depletion of mitochondrial GSH upregulates GSH
production in the cytosol, but despite this the mitochondrial
pool is still depleted. Note that the levels of GSH were assessed
against time of day-matched controls to allow for the known
diurnal variation in cell and mitochondrial GSH levels (Blanco
et al., 2007), and that injection of carrier solvent (EtOH) did not
affect GSH levels (Figure S6B). The effect of MitoCDNB on
TrxR activity in vivowas assessed by analyzing cellular andmito-
chondrial fractions from liver isolated from MitoCDNB-injected
mice (Figure 5H). It was clear that MitoCDNB did not affect total
cellular TrxR activity, but did inhibit that in mitochondria (Fig-
ure 5H), which took up to 7 days post MitoCDNB injection to
show about 70% recovery. Together these data show that
MitoCDNB selectively depletes mitochondrial GSH and inhibits
mitochondrial TrxR in vivo. Intriguingly, cellular GSH and the en-
zymes used to synthesize it are upregulated in response to
mitochondrial GSH depletion, suggesting a retrograde signaling
pathway from mitochondria to the nucleus upon mitochondrial
GSH depletion.
Applications of MitoCDNB In Vitro and In Vivo
We have shown that MitoCDNB alters mitochondrial GSH con-
tent and TrxR2 activity selectively in cells and in vivo, without
affecting cytosolic thiol redox homeostasis. We next assessed(E) GSH depletion byMitoCDNB in vivo. Mitochondrial and whole tissue fractions
a percentage of control mice culled at the same time. The levels of GSH in the wh
kidney = 1.71 ± 0.3, 2.14 ± 0.52; heart = 4.15 ± 0.54, 2.36 ± 0.1 (nmol GSH/mg p
(F and G) Expression of g-glutamylcysteine ligase (gGCL) and glutathione synthet
and GS were analyzed by western blot (F). Each lane is a separate mouse, and q
(H) Liver and mitochondrial fractions at indicated times after MitoCDNB injection
Data are means ± SEM, N = 4 or 5 (E). *p < 0.05, **p < 0.01, ***p < 0.001 relativethe utility of MitoCDNB in experiments that require the selective
disruption of mitochondrial thiol redox state that would not have
been possible before the development of MitoCDNB.
MitoCDNB affects TrxR2, Prx3, and GSH, all of which are
important in degrading H2O2 within mitochondria, and further-
more inhibition of TrxR can enhance peroxide production (Zhong
et al., 1998). Therefore we assessed its impact on mitochondrial
H2O2 release (Figure 6A). Heart mitochondria incubated with
MitoCDNB alone did not enhancemitochondrial H2O2 efflux (Fig-
ure 6A). However, when H2O2 efflux was amplified usingMitoPQ,
which generates superoxide within mitochondria (Robb et al.,
2015), H2O2 efflux was further enhanced by MitoCDNB (Fig-
ure 6A). When MitoCDNB was added to cells and mitochondrial
ROS production assessed by MitoSOXRed using confocal
microscopy (Figure 6B) or flow cytometry (Figure 6C) there was
an increase in basal MitoSOXRed oxidation that was greatly
enhanced by MitoPQ. Thus, selectively disrupting the mitochon-
drial thiol system with MitoCDNB enhances mitochondrial
ROS efflux by selectively decreasing mitochondrial antioxidant
defenses.
Mitochondria are highly dynamic organelles, constantly
dividing, fusing and moving in response to cellular needs and
also to modulate the cellular metabolic state (Pernas and Scor-
rano, 2016). Mitochondrial dynamics have recently been linked
to the cellular thiol redox homeostasis (Willems et al., 2015), for
example, with the accumulation of GSSG in the cytosol and
intermembrane space leading to mitochondrial hyperfusion
during cellular stress (Mattie et al., 2018; Shutt et al., 2012).
However, the relative contributions of cytosolic and mitochon-
drial thiol redox states to organelle dynamics has been difficult
to assess. Thus, MitoCDNB gives us the opportunity to specif-
ically assess whether changes in mitochondrial thiol redox state
alone affected mitochondrial plasticity in the absence of thiol
changes in the cytosol. Live cell imaging of C2C12 cells tran-
siently expressing the mitochondrial marker, MitoGFP, showed
no mitochondrial fragmentation in control cells (Video S1), nor
with cells incubated with the control TPMP (Video S2). However,
addition of MitoCDNB for 30 min led to a rapid fragmentation of
the mitochondrial network (Video S3). To confirm the effect of
MitoCDNB on mitochondrial fragmentation observed by live
cell imaging, mitochondrial morphology was then quantified by
confocal microscopy on fixed cells. Mitochondrial morphology
was classified as tubular, intermediate and fragmented, and
analyzed from cells treated with various concentrations of
MitoCDNB, the negative control TPMP and FCCP, known to
inducemitochondrial fragmentation (Cereghetti et al., 2010) (Fig-
ures 6D and 6E). This analysis using MitoCDNB confirmed that
the selective disruption of mitochondrial thiol homeostasis was
sufficient to induce significant mitochondrial fragmentation (Fig-
ures 6D and 6E), and this occurred without a significant change
in mitochondrial mass, analyzed by quantification of the of thefrom liver, heart, and kidney at various times after MitoCDNB injection. Data are
ole tissue and mitochondria, respectively, were: liver = 30.56 ± 3.7, 3.71 ± 0.6;
rotein).
ase (GS). Mice were injected with MitoCDNB and 24 hr later liver levels of gGCL
uantified relative to GAPDH (G).
were assessed for TrxR activity.
to control, time zero (H), or time-matched controls (E). See also Figure S6.
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Figure 6. Selective Disruption of Mitochondrial Thiol Redox State Enhances Mitochondrial ROS Production, Mitochondrial Fragmentation,
and Retrograde Signaling
(A) MitoCDNB enhances mitochondrial H2O2 production. Heart mitochondria (70 mg protein) were incubated with MitoCDNB (10 mM) or vehicle for 10 min then
MitoPQ (5 mM) or vehicle was added and H2O2 production measured for 5 min. Data are means ± SEM, N = 4. ***p < 0.001 relative to control;
###p < 0.001 relative
to control + MitoPQ.
(B) MitoCDNB effect on mitochondrial ROS production in cells by confocal microscopy. Representative maximum projections of ROS production measured by
MitoSOX fluorescence in C2C12 myoblasts at 0 or 30 min after 5 mMMitoPQ addition. Myoblasts were incubated with MitoSOX (5 mM) and either 0.1% ethanol
(control) or MitoCDNB (10 mM) for 10min prior to MitoPQ addition. Red is oxidized MitoSOX and blue is DAPI nuclear staining. Scale bar, 20 mm. The graph is fold
change relative to control. Data are means ± SEM, N = 3. *p < 0.05, **p < 0.01.
(legend continued on next page)
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mitochondrial outer membrane marker protein TOM20 by west-
ern blot (Figure S6C).
MitoCDNB injection into a mouse led to an increase in the
expression of GCL (Figures 5F and 5G). As MitoCDNB only
affected the thiol redox status of the mitochondrial matrix, this
finding suggests that alterations to mitochondrial thiol redox
are communicated to the nucleus and there affect transcription.
To assess this possibility in more detail we assessed the effect of
MitoCDNB on transcription within mice in vivo (Figures 6F and
6G). Mouse livers were isolated 1 and 4 hr after MitoCDNB injec-
tion and transcription levels compared with sham injections
using RNA sequencing. This analysis showed a dramatic change
in transcription in the liver 1 hr after MitoCDNB injection (Fig-
ure 6F). Interestingly, 4 hr after the injection the transcriptome
changes were far less than at 1 hr, as there were a total of
1,003 genes significantly differentially expressed at 1 hr but
only 351 at 4 hr, as is illustrated by principal-component analysis
(Figure S6D). The 20 genes that increased and the 20 that
decreased expression the most compared with controls within
1 hr of MitoCDNB injection are shown as a heatmap (Figure 6G).
This analysis further indicates that the changes in transcription
induced by MitoCDNB injection were far greater at 1 hr after in-
jection compared with 4 hr (Figure 6G). Together these findings
show that there is a rapid transcriptional response to changes
in mitochondrial thiol redox state. While beyond the scope of
this paper, future work using MitoCDNBwill enable us to analyze
how changes in mitochondrial thiol redox state lead to changes
in transcription. We conclude that MitoCDNB provides an impor-
tant tool in investigating the retrograde signaling pathways that
link mitochondria to transcriptional regulation in the nucleus.
DISCUSSION
The redox state of themitochondrial thiol systems is thought to be
a key determinant of cell function and stress response. However,
assessing this assumption has provendifficult due to the difficulty
of altering mitochondrial thiol redox homoeostasis without
affecting that of other cell compartments. Here we have shown
that this constraint can be overcome in cells and in vivo by a
chemical biology approach using MitoCDNB. A major attribute
of MitoCDNB is its selective accumulation within mitochondria,
hence it only acts on the mitochondrial thiol systems, leaving the
rest of the cell unscathed. The other vital property of MitoCDNB
is that it is both a GST substrate, enabling selective GSH deple-
tion, also a TrxR2 inhibitor, by reacting with the enzyme’s active
site selenol. Furthermore, MitoCDNBmoiety also blocks reactive(C) MitoCDNB effect on mitochondrial ROS production in cells assessed by flow
0.1% ethanol (control), or 10 mM of MitoCDNB, TPMP or CDNB. Data are means
(D) Representative maximum projection images of C2C12 myoblasts (upper pane
4 hr, and analyzed by confocal microscopy to visualize mitochondrial fragmentatio
are representative of 3 independent experiments. Scale bars, 20 mm.
(E) Quantification of mitochondrial morphology in C2C12 myoblasts assessed a
Mitochondrial morphology was assigned as tubular, intermediate or fragmente
3 independent experiments, 100 cells were counted for each condition. ***p < 0.
(F and G) Effect of MitoCDNB on the mouse transcriptome. Mice (six in each co
transcriptomes were analyzed by RNA sequencing 1 and 4 hr later. (F) Volcano p
after injection compared with control. (G) Heatmap of changes in expression for
injection.
See also Figure S6.thiols, such as those in Prx3, further inhibiting the ability of the
mitochondrial thiol system to deal with oxidative stress. The intro-
duction of MitoCDNB will enable the selective alteration of mito-
chondrial thiol redox state and facilitate understanding its role in
many areas, including mitochondrial ROS production, redox
signaling, and dynamics. These insights will enhance our ability
to address many critical biomedical questions, including xenobi-
otic detoxification, ischemia-reperfusion injury and neurodegen-
erativediseases.Moregenerally,MitoCDNB indicates howchem-
ical biology approaches coupled with intracellular targeting can
be used to gain insight into organelle function in cells and in vivo.
To date this has only been applied to mitochondria, utilizing the
membrane potential to drive the selective delivery. It should be
possible to extend these chemical biology approaches to other
organelles, utilizing other modes of targeting such as the low pH
of cell compartments like lysosomes, the oxidized thiol redox
state of the endoplasmic reticulum, or the presence of organ-
elle-specific enzymes to activate pro-versions of the compounds.
SIGNIFICANCE
Mitochondrial thiol redox status is a key way in which the cell
protects itself against oxidative stress and is also central
to mitochondrial redox signaling. However, in investigating
these processes up to now it has been difficult to isolate
the effects of mitochondrial thiol status from that elsewhere
in the cell. To overcome this challenge, we have developed a
mitochondria-targetedmolecule,MitoCDNB, that is accumu-
lated by mitochondria and there depletes the mitochondrial
GSH pool and inactivates TrxR2 and Prx3. These interactions
enable mitochondrial thiol redox status to be disrupted inde-
pendently of that elsewhere in the cell. Here, we demonstrate
that this approach can be used in cells and in vivo and, in
proof-of-principle experiments, show the effects of the se-
lective disruption ofmitochondrial thiol redox status onmito-
chondrial ROS production and redox signaling. MitoCDNB
should prove to be a useful tool for those investigating mito-
chondrial redox biology.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice and Rats
All procedures were carried out in accordance with the UK Animals (Scientific Procedures) Act of 1986 and the University of Cam-
bridge Animal Welfare Policy under project licence 70/8238 reviewed by local review committee. Wistar rats (003, wildtype, female)Cell Chemical Biology 26, 449–461.e1–e8, March 21, 2019 e2
and C57BL/6 mice (664, wildtype, male) were ordered from Charles River Laboratories UK (Margate, UK). Both were maintained in
pathogen-free facilities with ad lib food and water and used between 8-12 weeks (mice) and 10-12 weeks (rats). Animals were culled
by cervical dislocation with accordance to UK Home Office Schedule 1.
Cell Lines
C2C12 (female) andHEPG2 (male) cells were obtained fromAmerican TypeCulture Collection (ATCC). Bothweremaintained at 37C,
5%CO2 and 100% humidity. Cell media was changed every 2-3 days with passaging at <80% confluency and seeding at no higher
than 5 x 103 viable cells/cm2with a typical subcultivation ratio of 1:4-1:6. Cell media was DMEMmedia (4.5 g/L glucose, 1mMsodium
pyruvate, 2 mM Glutamax, 1.5 g/L sodium bicarbonate) with 10 % Foetal Bovine Serum, 100 U/mL penicillin and 100 mg/mL
streptomycin.
METHOD DETAILS
Chemical Syntheses
Reagents were obtained from commercial suppliers and used without further purification. Acetonitrile (ACN) was dried using a
Puresolv solvent. The reaction under an inert atmosphere was carried out using oven-dried glassware and solvents were added
via syringe. 1H, 13C and 31P NMR spectra were obtained on a Bruker AVIII spectrometer operating at 400, 101, and 162MHz, respec-
tively or a Bruker AVIII operating at 500, 126, and 162 MHz, respectively. All coupling constants were measured in Hertz. Deuterated
solvents contained trimethylsilane (TMS) as a reference compound. DEPT was used to assign the signals in 13C NMR spectra as C,
CH, CH2 and CH3. Mass spectra (MS) were recorded on a Jeol JMS700 (MStation) spectrometer for EI andCI or BrukerMicrotof-q for
ESI. A Shimadzu FTIR-8400S spectrometer was used to obtain infrared (IR) spectra. Purification by used a Biotage Isolera automated
system.
Chemical Synthesis of MitoCDNB, MitoGSDNB and N-MitoCysDNB
[4-(5’-Chloro-2’,4’-dinitrophenylamino)but-1-yl]triphenylphosphonium (MitoCDNB) methanosulfonate
1,5-Dichloro-2,4-dinitrobenzene (847 mg, 3.57 mmol, 1.1 eq.) was added to a stirring solution of (4-aminobutyl)triphenylphospho-
nium bromide (1.50 g, 3.25 mmol, 1.0 eq.) in dry ACN (10 mL) under an argon atmosphere. Anhydrous N,N-diisopropylethylaminee3 Cell Chemical Biology 26, 449–461.e1–e8, March 21, 2019
(1.30 mL, 7.50 mmol, 2.0 eq.) was added dropwise and the resulting solution stirred for 24 h at RT under an argon atmosphere. The
reaction mixture was concentrated under reduced pressure and redissolved in CH2Cl2. The solution was then washed with aquoeus
hydrochloric acid (0.5 M, 23 50 mL), dried over magnesium sulfate and concentrated under vacuum. The product was then purified
by column chromatography using a 25 g SNAP ultra cartridge [SiO2, CH2Cl2:MeOH (100:0/90:10)]. The product containing fractions
were concentrated under vacuum, redissolved in CH2Cl2 then washed with aqueous sodium methanesulfonate (0.5 M, 2 3 50 mL),
dried over magnesium sulfate and concentrated under vacuum to give the MitoCDNB as the methanesulfonate salt as a yellow foam
(940 mg, 46 %). Rf [SiO2, CH2Cl2:MeOH (95:5)]: 0.57. ʋmax (ATR): 3364 (NH), 3063 (CH), 2932 (CH), 1613 (NH), 1539 (NO), 1323 (NO)
cm-1. dH (500 MHz, CDCl3): 1.80-1.73 (2H, m, H2-2), 2.12 (2H, qn, J = 6.6 Hz, H2-3), 2.77 (3H, s, CH3), 3.68 (2H, q, J = 6.0 Hz, H2-4),
3.81-3.74 (2H, m, H2-1), 7.10 (1H, s, H-6’), 7.84-7.67 (15H, m, Ar-H), 8.51 (1H, t, J = 5.5 Hz, NH), 8.98 (1H, s, H-3’), dC (126 MHz,
CDCl3): 19.70 (d, J = 3.7 Hz, CH2), 21.55 (d, J = 51.7 Hz, CH2), 28.65 (d, J = 17.0 Hz, CH2), 39.69 (CH3), 42.23 (CH2), 116.80 (CH),
118.30 (d, J = 86.0 Hz, C), 126.85 (CH), 128.99 (C), 130.63 (d, J=12.5 Hz, CH), 133.70 (d, J=10.1 Hz, CH), 134.25 (C), 135.18
(d, J = 2.9 Hz, CH), 135.81 (C), 147.00 (C). dP (202 MHz, CDCl3): 24.51 (1P, s). LRMS (ESI
+): 534 [M+, 100]. HRMS: 534.1323.
C28H26N3O4P
35Cl requires M+ 534.1344.
{4-[5’-(S-glutathionyl)-2’,4’-dinitrophenylamino]but-1-yl}triphenylphosphonium (MitoGSDNB) chloride
Glutathione (58 mg, 0.19 mmol, 2.0 eq.) was added to a solution of MitoCDNB (60 mg, 0.095 mmol, 1.0 eq.) and NaHCO3 (22 mg,
0.26 mmol, 3.3 eq) in EtOH:H2O (1:1, 2.0 mL). The solution was stirred at RT for 3 h then concentrated under vacuum. The resulting
solid was dissolved in water and purified by reversed phase chromatography using a 12 g C-18 cartridge eluting a gradient of water:
0%/ 40% ACN over 10 column vols. The product-containing fractions were concentrated under vacuum to give the sulfide as
a yellow solid (43 mg, 54%). dH (400 MHz: MeOD): 1.85-1.95 (2H, m, PCH2CH2), 1.98-2.07 (2H, m, NCH2CH2), 2.15 (2H, q, J =
7.1 Hz, CH2CH2CONH), 2.66 – 2.48 (2H, m, CH2CONH), 3.21 (1H, dd, J = 14.6, 10.1 Hz, CHAHBS), 3.53-3.73 (8H, m, Gln CH, Gly
CH2, PCH2, NCH2, CHAHBS), 4.68 (1H, dd, J = 10.0, 3.6 Hz, Cys CH), 6.87 (1H, s, Ar-H), 7.70-7.90 (15H, m, Ar-H), 8.96 (1H, s,
Ar-H). dC (101 MHz: MeOD): 19.54 (d, J = 3.9 Hz, CH2), 20.90 (d, J = 51.5 Hz, CH2), 26.64 (CH2), 28.95 (d, J = 16.8 Hz, CH2),
31.75 (CH2), 33.60 (CH2), 41.63 (CH2), 43.24 (CH2), 52.09 (CH), 54.06 (CH), 108.27 (CH), 118.42 (d, J = 86.3 Hz, C), 126.15 (CH),
127.64 (C), 130.18 (d, J = 12.5 Hz, CH), 133.06 (C), 133.47 (d, J = 9.9 Hz, CH), 134.90 (d, J = 3.0 Hz, CH), 145.76 (C), 146.22 (C),
170.00 (C), 172.72 (C), 174.02 (C), 174.40 (C). dP (162 MHz: MeOD): 23.95 (s). HRMS (ESI): 805.2378. C38H42O10N6PS2 requires
M+, 805.2415
N-MitoCysDNB disulfide bis(trifluoroacetate)
L-Cysteine hydrochloride (32 mg, 0.19 mmol, 2.0 eq.) was added to a solution of MitoCDNB (60 mg, 0.095 mmol, 1.0 eq.) and
NaHCO3 (32 mg, 0.38 mmol, 4.0 eq) in EtOH:H2O (1:1, 2.0 mL). The solution was stirred at RT for 48 h then extracted into dichloro-
methane (2 x 10 mL). The organic layer was dried over magnesium sulfate and concentrated under vacuum. The resulting solid was
dissolved in MeOH (2 mL) and stirred overnight at RT. The product was then purified by RP-HPLC on a Shimadzu Prominence instru-
ment using a Phenomenex Kinetex EVO C-18 5 micron 250 x 10 mm column eluting isocratic MeOH:0.1% TFA (aq) (60:40, flow rate
5.0mL/min) to give the disulfide as the bis(trifluoroacetate) salt as a yellow solid (5mg, 10%). dH (400MHz, CD3CN): 1.77-1.84 (4H,m,
2 x PCH2CH2), 1.85-2.00 (presumed 4H obscured by NMR solvent, 2 x NHCH2CH2), 3.14 (2H, dd, J = 13.9, 6.4 Hz, 2 3 CHAHBS),
3.31-3.38 (4H, m, 2 3 PCH2), 3.40-3.50 (4H, m, 2 3 NHCH2), 3.61 (2H, dd, J = 13.9, 4.1 Hz, 2 3 CHAHBS), 4.70-4.74 (2H, m, 2 3
CHCO2H), 5.78 (2H, s, Ar-H), 7.67-7.75 (24H, m, Ar-H), 7.81-7.86 (6H, m, Ar-H), 8.23 (2H, t, J = 5.5 Hz, N-H), 8.74 (2H, d, J =
7.0 Hz, N-H), 8.96 (2H, s, Ar-H). dC (101 MHz, CD3CN): 20.28 (CH2), 21.90 (d, J = 51.6 Hz, CH2), 29.18 (d, J = 16.8 Hz, CH2), 41.45
(CH2), 42.43 (CH2), 55.48 (CH), 92.07 (CH), 118.76 (d, J = 86.4 Hz, C), 124.54 (C), 124.90 (C), 129.42 (CH), 130.82 (d, J = 12.5 Hz,
CH), 134.23 (d, J = 9.9 Hz, CH), 135.62 (d, J = 3.0 Hz, CH), 147.75 (C), 149.12 (C), 172.30 (C). dP (162 MHz, CD3CN): 23.81 (s).
dF (376 MHz, CD3CN): –76.45 (s). HRMS (ESI): 640.1489. C62H60O12N8P2S2Na2 requires (M – 2CF3CO2H + 2Na)
2+, 640.1516.
Analysis of Compound Reactivity
MitoCDNB and MitoGSDNB were stored as 10 mM stocks in ethanol (EtOH) and stored under argon at -20C. UV/visible spectra
and kinetic analyses were done using a UV2501PC spectrophotometer (Shimadzu) in a 1 mL quartz cuvette containing KCl
buffer (120 mM KCl, 10 mM HEPES, 1 mM EGTA, pH 7.2 (KOH) at RT, unless stated otherwise). MitoGSDNB formation was
measured at 328 nm using a difference extinction coefficient (D 3328 = 8.1 mM
-1 cm-1). GSDNB formation was measured at
340 nm (ε340 = 9 mM
-1 cm-1 ) (Habig et al., 1974b). Inhibition of GST by GSDNB/MitoGSDNB was assessed by measuring activity
of GST to conjugate GSH to acrolein and the resultant decrease in absorbance at 215 nm. Samples for RP-HPLC were prepared
by resuspension to 25 % (v/v) acetonitrile (ACN) containing 0.1 % trifluoroacetic acid (TFA), followed by centrifugation (16000 x g
for 10 min) and filtration of the supernatant through a syringe-driven 0.22 mm polyvinylidene difluoride (PVDF) filter unit (Millex, Milli-
pore). Samples were then loaded into a 2 mL sample loop and separated by RP-HPLC using a C18 column (Jupiter 300A, Phenom-
enex) attached to a Widepore C18 guard column (Phenomenex), all driven by a Gilson 321 pump. A flow rate of 1 mL/min was used
with a gradient of 0.1 % (v/v) TFA in water (Buffer A) and Buffer B at: (% B). 0-2 min; 5 %, 2-17 min; 5-100 %, 17-19 min; 100 %,
19-22 min; 100-5%. Absorbance was measured at 220, 328 or 340 nm using a UV-Visible detector (Gilson 151).
LC-MS/MS Analysis
A Waters Xevo TQ-S triple-quadrupole mass spectrometer was used for MS analysis. Electrospray ionization was in positive ion
mode; parameters were as follows: capillary voltage, 3.2 kV; cone voltage, 79 V; ion source temperature, 150C; collision energy,
45 V. Nitrogen and argon were used as the curtain and the collision gases, respectively. MitoCDNB, MitoGSDNB and MitoCysDNBCell Chemical Biology 26, 449–461.e1–e8, March 21, 2019 e4
fragmentation patterns were obtained by direct infusion of 50 nM compound in 20 % (v/v) ACN + 0.1 % (v/v) formic acid (FA) at
25 mL/min. Data were acquired for 1min. For determination of breakdown products, cell samples were extracted as described below,
diluted 1:100 into 20 % ACN/0.1% FA, and precursor scans were obtained by direct infusion at 50 mL/min; data was acquired for
1 min. LC-MS/MS analyses were carried out using a front end I-class Aquity LC system (Waters). Samples were cooled and 2 mL
injected using a 15 mL flow-through needle and RP-HPLC was carried out at 30C using an Acquity UPLC BEH C18 1.7 mm,
1 3 50 mm column (Waters). Buffers were 5 % (v/v) ACN/0.1 % (v/v) formic acid (FA) in water (MS buffer A) and 90 % (v/v)
ACN/0.1 % (v/v) FA (MS buffer B). A gradient was run at 200 mL/min: 0–0.3 min, 5 % B; 0.3–3 min, 5–100 % B; 4–4.1 min, 100–5
% B; 4.1–4.6 min, 5 % B. Eluent was diverted to waste at 0–1 and 4-4.6 min acquisition time using an in-line divert valve. Multiple
reaction monitoring in positive ion mode was used for compound detection. Transitions used were: MitoCDNB, 534>183;
MitoGSDNB, 805>183, d15-MitoB, 412>191, MitoCysDNB, 619>183. For each experiment standard curves were prepared using
known amounts of MitoCDNB, MitoGSDNB or MitoCysDNB, which were spiked with internal standard of 10 pmol d15-MitoB and
extracted in parallel with the samples. Standards and samples were quantified using MassLynx 4.1 software to determine the
peak area for MitoCDNB, MitoGSDNB and d15-MitoB and the standard curves were used to determine the amounts of MitoCDNB,
MitoGSDNB and MitoCysDNB present.
Sample Extraction for LC-MS/MS Analysis
Tissue homogenates and urine samples were extracted by mixing 1:1 with 95 % ACN + 0.1 % FA. Mitochondrial and cell pellets
were extracted by addition of 1 mL 95 % ACN + 0.1 % FA. Blood (45 mL was added to tubes containing 5 mL of 5 mM EDTA
and immediately centrifuged at 16,000 x g for 5 min. Plasma was then removed and mixed 1:1 with 95 % ACN + 0.1 % FA.
Samples were then kept on ice for 1 h, followed by centrifugation (16,000 x g for 10 min). Supernatants were re-centrifuged
(16,000 x g for 10 min) before filtration through a 0.45 mm polyethylene filter plate (Porvair Sciences). Filtered solutions were
then centrifuged (16,000 x g for 10 min) before overnight drying using a Genevac miVac Quattro concentrator. The dried extract
was resuspended in 200 mL 20 % ACN + 0.1 % FA, centrifuged (16,000 x g for 10 min) and the supernatant analysed by
LC-MS/MS.
Mitochondrial Isolation and Fractionation
For isolated mitochondrial studies and matrix preparation, livers, hearts and kidneys were prepared from rats or mice. In all cases
mitochondria were isolated by homogenisation using a dounce homogeniser followed by differential centrifugation at 4C. Liver
and kidney mitochondria were prepared in STE buffer (250 mM sucrose, 10 mM Tris, 1 mM EGTA, pH 7.4). Heart mitochondria
were isolated using STE buffer supplemented with 0.1 % (w/v) fatty acid free BSA. Homogenates were pelleted by centrifugation
at 700 x g for 5 min (heart) or 3000 x g for 3 min (liver and kidney). The supernatant was collected and centrifuged at 5,500 x g for
10 min (heart) or 10 000 x g for 10 min (liver and kidney). Mitochondrial pellets were resuspended in 1 mL (heart) or 10 mL (liver
and kidney) and re-centrifuged at 5,500 x g for 10 min (heart) or 10000 x g for 10 min (liver and kidney) prior to final re-suspension
in 100 mL per heart, 1 mL per kidney or 5 mL per liver.
Mitochondrial matrix was prepared by vortexing rat liver mitochondria (10 mg protein/mL) in STE, followed by 5 freeze-thaw cycles
(liquid nitrogen to RT). The suspension was then sonicated (10 cycles of 1 min at 50W followed by 5 min on ice using a Q700 mini-tip
sonicator, QSonica). The suspension was then centrifuged (205,000 x g for 1 h at 4C) and the resulting supernatant was centrifuged
once more, and the protein concentration determined by the BCA assay. Aliquots (1 mg protein/mL) were snap frozen on dry ice and
stored at -80C until use. In all cases protein concentration was measured using the bicinchoninic acid (BCA) assay with bovine
serum albumin (BSA) as a standard.
Mitochondrial Incubations
Mitochondrial incubations were in KCl buffer (120 mM KCl, 10 mM HEPES, 1 mM EGTA, pH 7.2) at 37C, with succinate (10 mM),
rotenone (4 mg/mL), FCCP (2 mM) added as appropriate, unless stated otherwise. After incubations mitochondria were pelleted by
centrifugation (7500 x g for 10 min) and pellets and supernatants analysed as necessary. An ion-selective electrode sensitive to
the triphenylphosphonium (TPP) cation moiety was constructed and used to measure accumulation of MitoCDNB into mitochondria
as described previously (Asin-Cayuela et al., 2004). Briefly, the TPP ion-selective electrode was constructed from a PVC membrane
incorporating a tetraphenylborate ion-exchanger and filled with an aqueous solution of 10 mM TPMP. The electrode and a Ag/AgCl
reference electrode were inserted through the air-tight Perspex lid of a stirred incubation chamber containing 3 mL incubation
buffer. Mitochondrial respiration was measured in 2 mL KCl buffer using an Oroboros O2k high resolution respirometer (Oroboros
Instruments, Austria). Measurements of hydrogen peroxide (H2O2) production by mitochondria was performed using a fluorometric
plate reader to assess conversion of Amplex Red to resorufin (SpectraMax geminiXS; Molecular Devices). Rat heart mitochondria
(70 mg protein) were incubated with 4 mg horseradish peroxidase (HRP), 4 mg MnSOD and 40 mg BSA in a final volume of 100 mL
KCl buffer in a 96 well plate. A further 100 mL KCl buffer was added containing 10 mM succinate and 85 mM Amplex Red. Resorufin
fluorescence was detected by excitation at 570 nm and emission at 585 nm and calibrated against known H2O2 concentrations
(43.6 M-1cm-1 at 240 nm). The membrane potential in isolated mitochondria was measured by the accumulation of radiolabelled
triphenylmethylphosphonium (TPMP) as described (Ross et al., 2006).e5 Cell Chemical Biology 26, 449–461.e1–e8, March 21, 2019
Cell Culture and Isolation of Mitochondria from Cells
C2C12 and HepG2 cells were maintained at subconfluency (< 80 %) at 37C in a humidified atmosphere of 95 % air and 5% CO2 in
Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco) with high glucose (4.5 g/L D-glucose), supplemented with 10 % (v/v) foetal
bovine serum (FBS), 100 U/mL penicillin and 100 mg/mL streptomycin. To measure cell growth, cells were typically seeded at
30,000 cells/well in 24-well plates and left to adhere for 16 h. Cells were then exposed to appropriate treatments and confluence
monitored using an IncuCyte HD (Essen Bioscience). Images of wells were taken in technical replicates of 4, every 4 h until maximum
confluence in control groups, and biological replicates performed on 3 separate cell passages.
To isolate mitochondria from cells (Clayton and Shadel, 2014), cells were grown up to 5-30 x 106/cm2 in Nuclon Delta treated
flasks (Thermo Fisher Scientific). After appropriate incubations, cells were detached using trypsin, pelleted (10000 x g for 3 min)
and resuspended in 11 mL RSB Hypo buffer (10 mM NaCl, 1.5 mM MgCl2, 10 mM Tris-HCl (pH 7.5)). After incubation on ice
for 10 min on ice cells were homogenised using a tight fitting Dounce homogeniser and then 8 mL 2.5 x hypertonic buffer
(575mMmannitol, 175mM sucrose, 12.5mMTris-HCl, 2.5mMEDTA (pH 7.5)) was added. The suspension wasmixed, and a sample
taken for total cell measurements. The homogenate was then made up to 30 mL using 1 x hypertonic buffer centrifuged (1300 x g
for 5 min) and the supernatant again centrifuged (12500 x g for 15 min). The pellet was then resuspended in STE buffer and
re-centrifuged.
For cell fractionation after mitochondrial fragmentation cells were grown up to 20 x 106 in 150mmdishes (Thermo Fisher Scientific).
After appropriate incubations, cells were detached using trypsin, pelleted (150 x g, 3 min, RT) and resuspended in 1mLMito isolation
buffer (MIB) (220mMD-Mannitol, 70mMSucrose, 1 mMEDTA, 10mMHEPES). Cells were homogenised using a tight fitting Dounce
homogeniser (Wheaton, USA) and a sample was taken as a whole cell fraction. The homogenate was centrifuged (800 x g, 10 min,
4C) and the pellet discarded. The supernatant was recentrifuged (800 x g, 10 min, 4C) and pellet discarded, with this step repeated
until no pellet was observed. The resulting supernatant was subsequently centrifuged (9000 x g, 10 min, 4C), collecting the
supernatant (S) and resuspending the pellet (P) in 1 mL of MIB. This step was repeated. The resuspended pellet (P) was centrifuged
(9000 x g, 15 min, 4C), the supernatant was discarded, and the pellet was resuspended in 50 ml MIB (crude mitochondrial fraction).
The supernatant (S) underwent an ultracentrifugation step (109,000 x g, 1 h, 4C) and the resulting supernatant was collected as the
cytosolic fraction. The protein concentration of each fraction was measured with a BCA assay (Thermo).
Flow Cytometry
To assess relative changes in mitochondrial ROS production C2C12 cells were isolated and suspended (0.5 x 106 cells/mL) in phenol
red-free DMEM (supplemented with 10 % (v/v) FBS) in an Eppendorf tube supplemented with MitoSOXRed (5 mM; Thermo Fisher
Scientific) and incubated with shaking in a 37C water bath for 20 min, in the dark. The cells were then pelleted (150 x g, 3 min,
RT) and resuspended in pre-warmed DMEM. At least 10,000 total events were acquired using a BD LSRFortessa cell analyzer
(BD Biosciences). MitoSOX Red was excited by laser at 532 nm, and the data were collected at forward scatter (FSC), side scatter
(SSC) and with 586/15 nm detector. The data were analysed using FlowJo software (version 10.4.2), with the cell debris, represented
by forward and side scatter, gated out for analysis. Median fluorescence intensity (MFI) of the 586/15 nm channel was measured as a
measure of mitochondrial reactive oxygen species production.
To measure cell death, C2C12 cells (300,000 cells) were grown overnight in a 6 well plate. Cells were harvested by trypsinisation
and resuspended in 2mLPBS. Test compoundswere added to cells and incubate on ice for 15min before addition of 1 mMpropidium
iodide for 10 min. Cells were then analysed using a BD Accuri Flow Cytometer. 10,000 events per sample were used and PI fluores-
cence measured using the FL2 channel, with PI excitation at 488 nm and emission at 617 nm. Initial gating controls were performed
using vehicle (0.1 % EtOH) for live cells and 1 % Triton X-100 for dead cells. Cell death was calculated by relative % of events in the
live/dead gates.
Glutathione Measurement
To determine the total glutathione pool (GSH + 2 x GSSG), mitochondria (1 mg protein), cells (1 x 106-9 cells) or tissue homogenate
(> 1 mg protein) were treated with 100 mL 5 % (w/v) sulfosalicylic acid with vortexing for 30 s, proteins precipitated by centrifugation
(16000 x g for 10 min) and the supernatant analysed by the GSH recycling assay as described (Akerboom and Sies, 1981) (Scarlett
et al., 1996). Data are expressed as glutathione equivalents (GSH + 2 x GSSG) normalised to protein determined by the BCA assay.
For tissues, an addition of 0.1 % (v/v) TX100 was made to the 5 % SSA solution.
Thioredoxin Reductase Activity
Measurement of TrxR activity was based on (Cunniff et al., 2013). Mitochondrial (1 mg protein) or cell pellets (1 x 106 cells) were pre-
pared by centrifugation (16000 x g for 10 min) and the pellet extracted in 100 mL NP-40 lysis buffer (150 mM NaCl, 1 % (v/v) NP-40,
50 mM Tris-Cl, pH 8.0) by resuspension and incubation on ice for 10 min. Samples were then centrifuged (16000 x g for 10 min) and
the supernatant retained. Protein concentration was calculated by BCA assay and then 25 mg protein was added per well of a 96-well
plate. Purified TrxR1 (Sigma; 100 mg) was in 250 ml PBS. The activity assay in 96-well plates was done by addition of 25 mg protein
sample, up to a final volume of 60 mL to which was added 40 mL of 1 mM NADPH and 2 mM selenocystine in NP40-lysis buffer was
added, and NADPH consumption measured at 340 nm (6.22 mM-1 cm-1) for 30 min using a SpectraMax platereader (Molecular
Devices). Control wells contained NADPH and protein and the background rate was subtracted from activity rates.Cell Chemical Biology 26, 449–461.e1–e8, March 21, 2019 e6
In Vivo Experiments
Mice were administered a 100 mL bolus by tail vein injection containing 5 mg/kg MitoCDNB in 0.9 % saline/5 % (v/v) EtOH final and
then culled at the indicated time points by cervical dislocation and tissues collected. The dosage was chosen based on other
TPP-compound tolerance levels in mouse models and showed no overt toxicity. Control mice were culled without injection or
injected as abovewith 0.9%saline/5% (v/v) EtOH final), at appropriate time points. Tissues or bloodwere extracted and immediately
prepared, as above.
Western Blotting
Samples were resuspended in 4X loading buffer (200 mM Tris-Cl, pH (6.8), 8 % (w/v) SDS, 0.4 % (w/v) bromophenol blue, 40 % (v/v)
glycerol), 400 mM DTT as a reductant. Typically 10-25 mg protein was loaded onto 12 % or 4 – 20% Tris-Glycine SDS-PAGE gels
(BioRad) and run at 120 V for 45 min. Protein was transferred to PVDF membranes (Immobilon-FL or BioRad Trans-Blot
TurboMini) by wet transfer (in the presence of 25 mM Tris, 192 mM glycine, 20% (v/v) methanol, pH (8.4)) or semi-dry transfer
(BioRad Trans-Blot Turbo) before blocking for 1 h at RT with Odyssey blocking buffer (LICOR). Typically, primary antibody incu-
bation was completed in 4 % (v/v) Odyssey buffer in PBS + 0.1 % (v/v) Tween-20 (PBST) for 1 h at RT. Membranes were then
washed 3 x 15 min in PBST, followed by secondary incubation in 4 % Odyssey buffer in PBS for 1 h at RT, washed 2 x 15 min in
PBST and 1 x 15min in PBS. Membranes were then visualised using a LICOROdyssey CLx system and analysed using ImageStudio
Lite. Primary antibodies: rabbit anti-TPP (1:1000) (Lin et al., 2002), rabbit anti-TrxR (1:1000, Abcam), rabbit anti-Prx3 (1:500, Abcam),
mouse anti-Trx (1:1000, Abcam) mouse anti-Prx2 (1:4000 Abcam). Secondary antibodies were goat anti-rabbit IRDye800 (1:25000,
LICOR) and goat anti-mouse IRDye680 (1:25000, LICOR).
Peroxiredoxin Assays
C2C12 cells were plated in 6 well plates at 25,000 cells/cm2 and after 2 days were treated with test reagents. After cell incubation the
media was aspirated, and cells incubated in 2 mL fresh media containing 80 mMmethylmethanethiosulfonate (MMTS) for 10 min at
RT. Then medium was aspirated, cells washed in ice cold PBS and then lysed with 150 mL RIPA lysing buffer (50 mM Tris, pH (8.0),
150 mMNaCl 1% (v/v) Triton-X100 (Tx100), 0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate), supplemented with soybean trypsin-
chymotrypsin inhibitor (4 mg/mL), phenylmethanesulfonyl fluoride (0.1 mM)) and MMTS (80 mM) and scraped into 1.5 ml Eppendorf
tubes. Lysates were centrifuged (16,000 x g for 10 min at 4C) and protein concentration was estimated using a BCA assay of
an untreated control without MMTS. Protein (50 mg) was then analysed by Western blotting as above with primary antibodies
used; mouse anti-Prx2 (1:4000) and rabbit anti-Prx3 (1:500) antibodies (Abcam). Membranes were visualised as described above.
Prx dimerization was calculated from monomer and dimer signal intensities (SI) as follows: % dimer = (SI dimer / ((SI dimer + SI
monomer)) x 100) % dimer was then expressed relative to untreated controls.
Immunocytochemistry
C2C12 cells were plated at 15,000 cells/well in 24-well plates containing glass coverslips. After 16 h the compounds of interest were
added. At the end of the incubation the media was removed, cells were washed twice in PBS, fixed with 4 % (w/v) formaldehyde in
PBS for 10 mins at RT followed by washing 3 x 10 min with PBS. Cells were then permeabilised with 0.1 % (v/v) Tx100 in PBS for
10 min, washed (3 x 10 min PBS), blocked with 5 % (w/v) BSA in PBS-T for 20 min at RT, and then incubated with primary antibody
in 5 % (w/v) BSA in PBS for 2 h at RT. Primary antibody solution was removed, cells washed (3 x 10 min PBS) and incubated with
secondary antibodies in 5 % (w/v) BSA in PBS for 1 h at RT. This solution was then removed and cells washed (3 x 10 min in
PBS). Coverslips were then mounted onto slides using Dako Mounting Medium (10 mL/coverslip; Agilent) and analysed using Andor
Dragonfly spinning disk confocal microscope equipped with a Nikon Plan-Apochromat 100x/1.45 NA oil immersion objective and a
Zyla 4.2 SCMOS camera (ANDOR). Z-stacks were acquired at 0.2-mm steps. Representative images for each condition were taken
from >30 cells and sorted by a blinded colleague into tubular, intermediate and fragmented mitochondrial categories (Morita et al.,
2017). This process was repeated on three separate cell passages to ensure biological replication. Primary antibody was rabbit
anti-TOMM20 (1 in 1000; Santa Cruz Biotechnology). Secondary antibodywas AlexaFluor594 goat anti-rabbit (1:1000; Thermo Fisher
Scientific). Images processing was performed using ImageJ software.
Confocal ROS Measurements
C2C12 cells were plated at 75,000 cells in 27 mm Nunc Glass Bottom Dishes (Thermo Fisher Scientific). The next day cells were
washed x 2 with pre-warmed PBS and incubated with MitoSOX (5 mM; Thermo Fisher Scientific) in full growth medium. Cells
were washed three times in Krebs buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.25 mM CaCl2, 1.2 mM KH2PO4, 25 mM
NaHCO3, 11mMglucose) and placed on the live cell imaging incubator (OKO lab) with 5%CO2 and 37
C. Acquisition was performed
using a Nikon A1-R confocal microscope equipped with a Nikon Plan-Apochromat 60x/1.4 N.A. objective. Z-stacks were acquired
at 0.5 mm steps of at least 10 cells per condition. Cells were imaged before (0 min) and after (30 min) MitoParaquat (5 mM) addition
and the fluorescence intensity in the cytosol was quantified by Fiji (Image J) (Schindelin et al., 2012).
Mitochondrial Dynamics
For live imaging, C2C12 cells were plated at 50,000 cells/well in 6 well plates with glass coverslips pre-installed. After 24 hours,
cells were transfected with 1 mg of MitoGFP (Addgene;#50057) using lipofectamine according to manufacturer’s instructions.e7 Cell Chemical Biology 26, 449–461.e1–e8, March 21, 2019
After 48 h the coverslip containing cells was removed from the well and installed into a metal coverslip holder containing 2mL DMEM
media. Cells were then visualised by a Zeiss LSM880 confocal system equipped with a Zeiss Plan-Apochromat 63x/1.4 N. A. Cells
were visualised and focussed on the system before initiation of data capture, and after 5 min of control phase compounds of interest
were then added. Cells were visualised for 1 h with images taken every 1 min at 4 pre-distinguished coordinates.
RNA Extraction and Sequencing
For RNA extraction from tissues, the medial lobe of the mouse liver was collected into RNAlater (Invitrogen). Tissue (30 mg wet
weight) was retrieved after 2 hours from the storage solution, placed in PureLink RNA Mini Kit lysis buffer (Invitrogen) in a Precellys
tube (Soft tissue homogenising CK14 – 2mL; Bertin Instruments) and homogenised twice using a Precellys 24 tissue homogeniser
(6,500 rpm, 15 seconds: Bertin Instruments). RNA was extracted using a PureLink RNA Mini Kit (Invitrogen) with the RNA eluted
into 80 ml RNA-free water and immediately placed on ice. The 260:280 and 260:230 UV absorption ratios were assessed using a
NanoDrop spectrophotometer. The RNA concentration and RNA integrity number (RIN) were determined using the Agilent 4200
TapeStation System and RNA ScreenTape (Agilent Technologies) and samples with a RIN > 8 were used for downstream analysis.
Subsequent RNA preparation and sequencing was done by Novogene. The mRNA was purified from total RNA using NEBNext
Poly(A) mRNA Magnetic Isolation Module (New England Biolabs). First- and second-strand cDNA were synthesized using NEBNext
synthesis modules (New England Biolabs) and purified using Agencourt AMPure XP beads (Beckman Coulter). RNA library prepara-
tion was done using NEBNext Ultra RNA Library Prep kit for Illumina (New England Biolabs). Libraries were pooled and sequenced on
a HiSeq X Ten platform (Illumina) with paired-end 150 bp (PE 150) sequencing strategy by Novogene.
QUANTIFICANTION AND STATISTICAL ANALYSIS
Statistical Analysis
Statistical comparison between two groups was carried out using GraphPad Prism 5 software using two-tailed Student’s t tests.
Number of biological replicates (n) and statistical values can be found in each figure legend. In vitro n = independent experiments
whereas in vivo n = individual animals. *p < 0.05, ** p < 0.01, ***p < 0.001.
Transcriptomic Analysis
The resulting sequencing BCL files were demultiplexed with CASAVA to FASTQ files. These were processed to remove low quality
reads and adapter sequences using TrimGalore! and quality of the sequencing data was confirmed using FASTQC. Reads were
aligned to the mm10 (Mus musculus; Dec 2011, Genome Reference Consortium GRCm38) genome using hisat2 and a count table
produced using Featurecounts from RSubread. Normalisation and differential expression analysis was carried out using DESEQ2
within the R statistical environment.
Data and Software Analysis
GraphPad Prism 5 was used for statistical analysis and graph production. CASAVA, TrimGalore!, FASTQC, Hisat2, Featurecounts
from Rsubread and DESEQ2 in R platform were used in the processing and analysis of transcriptomic data with details above.
DATA AND SOFTWARE AVAILABILITY
The accession number for RNASeq data reported in this paper is PubMed GEO: GSE117425. Methods to obtain the data are ex-
plained above.Cell Chemical Biology 26, 449–461.e1–e8, March 21, 2019 e8
